People News: Abbott Labs and Lux Biosciences
Abbott Laboratories executive vice president of pharmaceuticals Olivier Bohuon is leaving the company to become CEO at Pierre Fabre Group, a French pharmaceutical company, beginning September 1. Richard Gonzalez, a former president and COO at Abbott, will lead Abbott's pharmaceutical division on an interim basis, according to an Associated Press report. Abbott's pharmaceutical division is responsible for the lion's share of the company's total revenue, due mostly to Humira, a blockbuster injection indicated for rheumatoid arthritis, Crohn's disease and other inflammatory conditions. The pharmaceuticals division pulled in $4.1 billion in sales for the first quarter of 2010, according to the AP.
Lux Biosciences hired Dean Mitchell as president and CEO. Mitchell had been president and CEO of Alpharma before that company was acquired by King in 2008.